Renal protective effects of benidipine and valsartan in primary hypertension patients with proteinuria.
- Author:
Tao PENG
1
;
Zhao HU
;
Ling GUO
;
Xiang-dong YANG
;
Qing XIA
;
Xian-hua LI
;
Bei JIANG
;
Fei PEI
;
Jian SONG
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Angiotensin Receptor Antagonists; therapeutic use; Calcium Channel Blockers; therapeutic use; Dihydropyridines; therapeutic use; Female; Glomerular Filtration Rate; Humans; Hypertension; complications; drug therapy; Male; Middle Aged; Proteinuria; complications; drug therapy; Tetrazoles; therapeutic use; Valine; analogs & derivatives; therapeutic use; Valsartan
- From: Chinese Journal of Cardiology 2010;38(1):20-22
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo compare the renal protective effects between calcium channel blocker benidipine and angiotensin II receptor blocker valsartan in primary hypertension patients with proteinuria.
METHODSA total of 236 patients were divided to low (< 1 g/24 h) and high (1 - 3 g/24 h) proteinuria groups and treated with benidipine (8 mg/d) or valsartan (80 mg/d) for 48 weeks. Blood pressure, glomerular filtration rate (GFR) and 24 h protein were measured at baseline, 12, 24 and 48 weeks.
RESULTSBlood pressure was significantly and equally reduced in all treated groups (all P < 0.05 vs. baseline). GFR was also significantly and equally improved in all treated groups after 24 weeks treatments (all P < 0.05 at 24 weeks and 48 weeks). Proteinuria reduction at 24 and 48 weeks was more significant in patients treated with valsartan compared to patients treated with benidipine in low proteinuria group [24 weeks: (0.27 +/- 0.07) g/24 h vs. (0.39 +/- 0.06) g/24 h, P < 0.01; 48 weeks: (0.18 +/- 0.01) g/24 h vs. (0.30 +/- 0.05) g/24 h, P < 0.01].
CONCLUSIONThe renal protection efficacy of valsartan and benidipine was similar in primary hypertensive patients with proteinuria.